First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted &lt;sup&gt;212&lt;/sup&gt;Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.